What is your current practice for obtaining mutation status for a patient with newly diagnosed ovarian cancer?  

My current practice is to test all newly diagnosed epithelial ovarian cancer patients (includes fallopian tube and peritoneal) with both germline multigene and somatic multigene/NGS panels. Only recently have I adopted the practice of concurrent testing at diagnosis rather than basing the decision t...

Currently, patients with newly diagnosed epithelial ovarian cancer undergo germline genetic testing using the Myriad MyRisk platform. This allows for integrated reflex testing with Myriad MyChoice (in the context of negative gremline BRCA testing), capturing somatic BRCA, as well as HRD status. In p...

All ovarian patients at our center get referred for comprehensive genetic testing (to look for germline mutations). Some of these platforms will reflex negative germline testing to somatic testing. If that is not done in a particular case, then we will send tissue for Myriad MyChoice testing to obt...